Loomis, Sayles & Company
PRAH

Loomis, Sayles & Company’s PRA Health Sciences, Inc. PRAH Stock Holding History

Loomis, Sayles & Company’s Portfolio PRAH Stock Details PRAH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-703,970
Closed -$116M – 955
2021
Q2 		$116M Sell
703,970
-1,373
-0.2% -$229K 0.14% 72
2021
Q1 		$108M Sell
705,343
-1,341
-0.2% -$182K 0.14% 65
2020
Q4 		$88.6M Buy
706,684
+21,635
+3% +$2.42M 0.12% 76
2020
Q3 		$69.5M Buy
685,049
+7,636
+1% +$779K 0.1% 77
2020
Q2 		$65.9M Buy
677,413
+57,148
+9% +$5.32M 0.11% 78
2020
Q1 		$51.5M Buy
620,265
+879
+0.1% +$85.7K 0.11% 75
2019
Q4 		$68.8M Sell
619,386
-14,699
-2% -$1.51M 0.12% 65
2019
Q3 		$62.9M Buy
634,085
+111,237
+21% +$11M 0.12% 68
2019
Q2 		$51.8M Buy
522,848
+37,335
+8% +$3.56M 0.1% 87
2019
Q1 		$53.5M Buy
485,513
+90,346
+23% +$9.44M 0.11% 78
2018
Q4 		$36.3M Buy
395,167
+6,709
+2% +$679K 0.09% 92
2018
Q3 		$42.8M Sell
388,458
-4,333
-1% -$451K 0.08% 94
2018
Q2 		$36.7M Buy
392,791
+24,607
+7% +$2.12M 0.07% 121
2018
Q1 		$30.5M Sell
368,184
-13,329
-3% -$1.18M 0.06% 148
2017
Q4 		$34.7M Sell
381,513
-3,546
-0.9% -$295K 0.07% 142
2017
Q3 		$29.3M Buy
385,059
+17,873
+5% +$1.35M 0.06% 186
2017
Q2 		$27.5M Sell
367,186
-12,518
-3% -$868K 0.06% 189
2017
Q1 		$24.8M Sell
379,704
-8,474
-2% -$499K 0.06% 204
2016
Q4 		$21.4M Sell
388,178
-19,732
-5% -$1.08M 0.05% 249
2016
Q3 		$23.1M Buy
407,910
+97,594
+31% +$4.79M 0.06% 220
2016
Q2 		$13M Buy
310,316
+310,132
+168,550% +$14.3M 0.04% 382
2016
Q1 		$8K Buy
184
+120
+188% +$5.07K ﹤0.01% 876
2015
Q4 		$3K Buy
+64
New +$2.69K ﹤0.01% 975

Other funds holding PRAH

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Loomis, Sayles & Company's PRAH Position: Q3 2021 in Review

Loomis, Sayles & Company sold out of PRA Health Sciences, Inc. (PRAH) in Q3 2021, closing a stake of 703,970 shares — an estimated $116M sold.

Loomis, Sayles & Company first reported a position in PRAH in Q4 2015 and held it in 23 quarters. The position peaked at $116M in Q2 2021. 1 fund tracked by Wall St. Rank holds PRAH as of Q3 2021.

  • Loomis, Sayles & Company reported no remaining PRA Health Sciences, Inc. position as of Q3 2021 after selling out during the quarter.
  • Loomis, Sayles & Company sold 703,970 PRA Health Sciences, Inc. shares in Q3 2021, an estimated $116M.
  • Loomis, Sayles & Company first reported a position in PRA Health Sciences, Inc. in Q4 2015 and held it in 23 quarters.
  • Loomis, Sayles & Company's PRA Health Sciences, Inc. position peaked at $116M in Q2 2021.
  • 1 fund tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q3 2021.

Based on Loomis, Sayles & Company's 13F filing for Q3 2021, filed 12 Nov 2021.